[ad_1]
You’re reading the web edition of STAT Health Tech, our guide to how tech is transforming the life sciences. Sign up to get this newsletter delivered in your inbox every Tuesday and Thursday.
Holmes admits to one key misstep in Theranos debacle
Since Elizabeth Holmes first took the stand, she’s stuck to the case her lawyers promised from day one of the now 13-week-long trial: pass the buck. The Theranos founder has pointed the finger at others for failings in her company’s assays (the lab director and other hires) and financial projections (COO Sunny Balwani). But in her four days of testimony so far, Holmes has admitted to at least one important misstep. In Theranos-produced lab reports provided to Walgreens in 2010, Holmes herself added the logos of Pfizer and Schering-Plough, which suggested, inaccurately, the reports came from the pharma companies themselves. Though Holmes testified it wasn’t her intent to mislead, the admission could impact the jury’s opinion of whether Holmes intentionally defrauded investors.
advertisement
On Monday, though, Holmes delivered the testimony perhaps most likely to sway jurors in her favor. Responding to questions from her lawyer about her romantic and professional relationship with Balwani, she alleged both verbal and sexual abuse. Holmes testified that Balwani didn’t force her interactions with investors or business relationships, but described controlling and berating behavior. “He impacted everything about who I was,” she said. “And I don’t fully understand that.” Holmes’ trial will continue today, with her cross examination expected to take most of the session. After breaking the rest of this week, the court calendar resumes on December 7, with dates running through the 17th.
A boom or bust Black Friday
advertisement
The worst Black Friday trading day on record wasn’t all bad for the digital health sector. Investor fears of the Omircon variant offered a temporary boost to companies such as Teladoc, Amwell, 23andMe, and many others. It’s becoming a tried-and-true pandemic formula for investors and digital health companies. But keep in mind that the fickle financial markets are operating on pure emotion at this point, with little scientific evidence to support the fears of Omicron — or any fortunes to be made from it.
The global race for AI funding heats up
U.S. companies are getting the largest share of a sharp increase in global funding for artificial intelligence products and services, according to a new report from CB Insights. Within health care, investment in AI companies has already beat 2020’s full-year total by 29%, topping out at $8.5 billion at the end of the third quarter. The digital health sector as a whole is seeing larger fundings rounds, more unicorns, and a sharp increase in IPOs. All of this sets the stage for a sink-or-swim year for newly public companies in 2022.
Can AI reduce adverse drug events?
Adverse drug events cost about $28 billion a year, likely a lowball estimate due to under-reporting. But a new scoping review published in Lancet identified an array of circumstances in which machine learning algorithms could help prevent adverse drug events or identify them earlier. The review highlighted cases in which AI could flag which patients are most likely to have a future adverse event or predict therapeutic responses to medications. It also examined the use of AI to provide early warning of adverse events to clinicians, allowing them to improve response times. While a promising area of inquiry, most of the studies reviewed in the paper only examined technical performance, not clinical evaluation of the algorithms.
Amazon scores a big cloud client & Luma Health raises $130M
- Amazon inked a big cloud contract with the pharmaceutical giant Gilead, which has already moved about 50% of its data center footprint into Amazon over the past year. The company said it’s hoping increased access to AI and analytics services will improve biomarker discovery, manufacturing, and clinical trial recruitment.
- The South Korean company Lunit, which uses AI for cancer screening and treatment recommendations, raised $61 million from new investors such as HealthQuest Capital and Casdin Capital. The company is set to go public on the South Korean market early next year.
- The patient-provider communications company Luma Health raked in $130 million in a Series C round led by FTV Capital. The company is hoping to enhance a communications platform used by 550 clients, including Banner Health and Montefiore Medical Center.
- Philadelphia-based CareAlign, a developer of care coordination software, raised $2.3 million from Hofmann Associates, Gaingels, and Harvard Angels. The company plans to expand its sales force and product offerings.
New talent
- New Cerner CEO David Feinberg is pulling some hires from his old digs. The EHR giant named Johnny Luu as its new chief communications officer, after leading comms at Google Health.
- Medtech company Becton, Dickinson has a new chief scientific officer: Joseph Smith joins from his holding company Digital Health Corp. after stints at Johnson & Johnson and Boston Scientific. BD has also installed a new scientific advisory board.
- Axuall, a company with a blockchain-based clinician credential platform, has made two senior hires: Joey Blogna as director of talent acquisition and development, and LaShawn Fergus, previously at Oneview Health, as director of implementation.
What we’re reading